Factors for early tumor recurrence of single small hepatocellular carcinoma after percutaneous radiofrequency ablation therapy

Table 2 Results of RFA in 22 patients with long-term follow-up.

Total sessions of RFA	26
One session/ Two sessions	18/4
Average sessions	1.20.4
Ablative time (min, range)	21.3±13.7 (3-48)
F/U1 duration (mo, range)	28.8±9.0 (15-45)
Roll-off (+/-)	21/1
Complications
Local pain	11
Nausea/vomiting	4
Fever	1
Local-free interval (M2, range)	22.2±10.0 (4-45)
Tumor-free interval (M2, range)	18.5±11.4 (2-45)
Local recurrence rate
12M/24M/30M	13.6% / 33.3% /46.6%
Overall recurrence rate
12M/24M/30M	36.4%/56.2%/56.2%
Survival interval (M2, range)	28.7±9.1 (15-45)
Pre-RFA / Post-RFA3
Albumin (g/dL)	3.8±0.5/4.20.6
GOT (U/L)	63.5±32.9/70.434.2
GPT (U/L)	71.1±40.0/79.234.2
T. Bili.4 (mg/dL)	1.1±0.5/1.00.5
Alk-P5 (U/L)	116.0±46.3/123.546.1
AFP6 level (ng/mL)
Pre-treatment (range)	223.5±663.1 (3-2870)
Post-treatment	41.3±90.6 (3-422)
Decrease AFP > 50% post RFA
Yes / No	8/14

¹F/U: Follow-up

² M: months

³Data of pre-RFA / Data of post-RFA

⁴T. Bili: total bilirubin level

⁵Alk-P: alkaline phosphatase level

⁶AFP: alpha-fetoprotein.